Oragenics Partners with Sterling Pharma Solutions for ONP-002
In a recent announcement, Oragenics, Inc. (NYSE American: OGEN), a biotechnology firm dedicated to advancing intranasal therapeutics aimed at brain-related conditions, has secured a pivotal manufacturing agreement with Sterling Pharma Solutions. This well-established contract development and manufacturing organization (CDMO) boasts a robust network of U.S.-based facilities, positioning Oragenics to effectively advance its lead drug candidate, ONP-002, which is focused on treating concussions.
Ensuring Compliance and Quality in Drug Production
This manufacturing partnership is set to facilitate the Good Manufacturing Practice (GMP) production of ONP-002, critical ahead of the anticipated Phase IIb clinical trials. With these trials on the horizon, this collaboration signifies a crucial milestone for Oragenics, solidifying its domestic production capabilities essential for both clinical and regulatory success.
Statements from Leadership
Janet Huffman, the Chief Executive Officer of Oragenics, expressed her enthusiasm about this partnership. She stated, “We are excited to partner with Sterling’s facility in Cary, North Carolina, to support the production of ONP-002. This partnership is a critical milestone in our path forward for Phase IIb clinical trials. This partnership reinforces our commitment to quality, efficiency, and U.S.-based innovation and we believe this step will help streamline our clinical development strategy.”
The Importance of ONP-002 Trials
ONP-002 will be produced under stringent cGMP conditions, ensuring that it meets the high standards required for the planned Phase IIb trials. This stage will serve as a proof-of-concept study, aiming to assess the early efficacy of ONP-002 in individuals suffering from mild traumatic brain injury (mTBI), commonly referred to as a concussion.
Collaborative Efforts in CNS Therapies
Chad Telgenhof, the Chief Commercial Officer of Sterling Pharma Solutions, also shared his perspective, stating, “We are pleased to be partnering with Oragenics for the GMP production of its lead molecule for clinical trials. Our scientific expertise in CNS therapies and our ability to meet critical timelines will support the continued path to market for this transformative drug candidate.”
Strategic Focus on Neurological Trauma Treatments
This U.S.-based manufacturing agreement aligns well with Oragenics’ broader strategic objectives aimed at developing scalable, efficient, and promptly accessible treatments for neurological trauma. As it stands, concussion remains a significant health challenge due to the absence of FDA-approved pharmacological therapies.
About Oragenics, Inc.
Oragenics is dedicated to innovating intranasal therapeutics specifically for neurological disorders. The lead candidate, ONP-002, represents a promising advancement in the treatment of mild traumatic brain injury. Leveraging its unique intranasal delivery technology, Oragenics aims to provide fast, targeted, and non-invasive therapeutic options that can effectively address brain health challenges.
Partner Profile: Sterling Pharma Solutions
Sterling Pharma Solutions, a prominent player in the contract development and manufacturing landscape, brings over 50 years of experience in delivering APIs and complex chemistry development services. With six facilities and a workforce of over 1,350 individuals, Sterling boasts a strong footprint that supports the pharmaceutical industry from proof-of-concept through to commercial manufacture.
Frequently Asked Questions
What is the focus of Oragenics, Inc.?
Oragenics focuses on developing intranasal therapeutics for neurological conditions, particularly mild traumatic brain injuries.
What is ONP-002?
ONP-002 is Oragenics' lead drug candidate aimed at treating concussions, utilizing an innovative intranasal delivery system.
Who is Sterling Pharma Solutions?
Sterling Pharma Solutions is a global contract development and manufacturing organization (CDMO) specializing in the production of pharmaceuticals and handling challenging chemistries.
What is the significance of the GMP production agreement?
The GMP production agreement ensures that ONP-002 meets regulatory quality standards necessary for upcoming clinical trials.
When will the Phase IIb clinical trials for ONP-002 start?
The Phase IIb clinical trials for ONP-002 are expected to commence in the near future, building on the initial proof-of-concept studies.
